Analyst Consensus ?
ConsensusHold43 ratings
Bullish2148.8%
Neutral1841.9%
Bearish49.3%
1 unmapped firm rating excluded from the percentages.
Albemarle Corporation · ALB · FY2024 Q3 · Calendar Q4 2024
Albemarle Maintains Outlook Amid Lithium-Price Pressure
The call provides mixed evidence for a durable growth case: demand from EV batteries and grid storage, specialty-chemicals demand, and facility ramps support the long-term opportunity, while lower lithium prices, a large loss, reduced capital spending, workforce cuts, and leverage constraints show that near-term earnings resilience remains unproven.
Reported After market closeNYSEBasic Materials
$11.27B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-1.55
Consensus $-0.31
EPS surprise
-400.0%
Reported versus consensus
Reported revenue
$1.35B
Consensus $1.44B
Revenue surprise
-6.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+3.5%
Event window
SPY move
+0.8%
Same window
Abnormal move
+2.7%
Stock minus SPY
Volume
1.6×
Versus trailing sessions
Subsequent drift
+5.0%
Up to 20 sessions
ALBSPY benchmark
Ask FN2 about ALB FY2024 Q3
Transcript, numbers and history already loaded
Why did ALB rise 3.5% after missing EPS estimates in FY2024 Q3?What changed in ALB's guidance and outlook in FY2024 Q3?Give me the bull and bear case for ALB after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management moved from a broad cost-and-operating-structure review to disclosed execution measures: a $300–$400 million savings target, sharply lower 2025 capital spending, an additional 6–7% workforce reduction, and an extended covenant waiver. The full-year outlook was maintained, but the call also highlighted the scale of lithium-price pressure and balance-sheet constraints.
Guidance delta
Management maintained the full-year 2024 outlook despite a significant Q3 loss and lower lithium prices.
Key takeaways
- Lower lithium prices drove a 41% year-over-year sales decline and a large GAAP loss in Q3 2024.
- Management emphasized energy-storage volume growth, specialty-chemicals demand, and new-plant ramps as offsets.
- The company is pursuing $300–$400 million of cost savings and sharply lower 2025 capital spending.
- A further 6–7% workforce reduction and an extended covenant waiver underscore the focus on liquidity and flexibility.
Management priorities
- Advance cost-reduction and productivity programs.
- Prioritize high-return brownfield expansions and ramp Salar and Magnolia.
- Continue direct-lithium-extraction pilots and maintain strategic joint-venture partnerships.
- Protect cash flow while managing lithium-market oversupply and leverage constraints.
Follow ALB with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$94.64Current
$68Low
$192.17Average
$320High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 20, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Outperform | Maintain | Oct 15, 2026 |
| Mizuho | Outperform | Neutral | Upgrade | Oct 14, 2026 |
| Argus Research | Buy | Buy | Maintain | Oct 7, 2026 |
| UBS | Buy | Buy | Maintain | Oct 5, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 25, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Aug 10, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 10, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Aug 10, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 7, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 7, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jun 4, 2026 |
| Berenberg | Hold | Hold | Maintain | Jun 2, 2026 |
| Vertical Research | Buy | Hold | Upgrade | May 26, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | May 13, 2026 |
| Baird | Neutral | Outperform | Downgrade | Apr 17, 2026 |
| Jefferies | Buy | Buy | Maintain | Jan 28, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jan 21, 2026 |
| Keybanc | Overweight | Downgrade | Jul 30, 2025 | |
| TD Securities | Hold | Hold | Maintain | May 1, 2025 |
| Piper Sandler | Underweight | Underweight | Maintain | Feb 20, 2025 |
| HSBC | Hold | Buy | Downgrade | Jul 17, 2024 |
| Loop Capital | Buy | Buy | Maintain | Mar 15, 2024 |
| TD Cowen | Market Perform | Outperform | Downgrade | Jan 29, 2024 |
| Credit Suisse | Underperform | Underperform | Maintain | Aug 3, 2023 |
| Goldman Sachs | Sell | Neutral | Downgrade | Dec 15, 2021 |
| Cowen & Co. | Outperform | Outperform | Maintain | Mar 10, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 11, 2020 |
| CFRA | Hold | Buy | Downgrade | Apr 3, 2020 |
| Seaport Global | Neutral | Buy | Downgrade | Nov 14, 2019 |
| Bank of America | Underperform | Buy | Downgrade | Oct 28, 2019 |
| Buckingham Research | Neutral | Neutral | Maintain | Oct 3, 2019 |
| Buckingham | Neutral | Neutral | Maintain | Oct 3, 2019 |
| Gabelli & Co. | Buy | Buy | Maintain | Sep 12, 2019 |
| Nomura | Neutral | Neutral | Maintain | Aug 9, 2019 |
| Argus | Buy | Buy | Maintain | Feb 23, 2018 |
| Macquarie | Outperform | Outperform | Maintain | Aug 19, 2015 |
| BB&T Capital | Buy | Buy | Maintain | Jul 8, 2015 |
| Topeka Capital | Buy | Hold | Upgrade | Jul 29, 2014 |
| Topeka | Buy | Hold | Upgrade | Jul 29, 2014 |
| Sterne Agee | Neutral | Buy | Downgrade | Oct 18, 2013 |
| PiperJaffray | Neutral | Overweight | Downgrade | Sep 24, 2013 |
| Gilford Securities | Hold | Buy | Downgrade | Jan 8, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $94.64. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Analyst unavailable | $129 | $97.75 | +36.3% | Oct 15, 2026 |
| Barclays | Analyst unavailable | $109 | $98.51 | +15.2% | Oct 12, 2026 |
| Argus Research | Analyst unavailable | $135 | $104.18 | +42.6% | Oct 7, 2026 |
| BMO Capital | Joel Jackson | $175 | $106.9 | +84.9% | Oct 6, 2026 |
| UBS | Joshua Spector | $150 | $104.59 | +58.5% | Oct 5, 2026 |
| Mizuho Securities | John Roberts | $130 | $105.78 | +37.4% | Oct 1, 2026 |
| Scotiabank | Ben Isaacson | $190 | $131.11 | +100.8% | Aug 10, 2026 |
| Morgan Stanley | Vincent Andrews | $161 | $131.11 | +70.1% | Aug 10, 2026 |
| Truist Financial | Peter Osterland | $225 | $128.49 | +137.7% | Aug 7, 2026 |
| UBS | Analyst unavailable | $175 | $128.86 | +84.9% | Aug 7, 2026 |
| RBC Capital | Analyst unavailable | $166 | $118.83 | +75.4% | Jul 17, 2026 |
| RBC Capital | Analyst unavailable | $257 | $177.4 | +171.6% | May 26, 2026 |
| Vertical Research | Analyst unavailable | $224 | $171.58 | +136.7% | May 26, 2026 |
| Scotiabank | Ben Isaacson | $215 | $191 | +127.2% | May 14, 2026 |
| Deutsche Bank | David Begleiter | $250 | $206.88 | +164.2% | May 12, 2026 |
| RBC Capital | Analyst unavailable | $253 | $216.2 | +167.3% | May 11, 2026 |
| Argus Research | Analyst unavailable | $230 | $215 | +143.0% | May 11, 2026 |
| UBS | Analyst unavailable | $264 | $198.01 | +179.0% | May 8, 2026 |
| Truist Financial | Analyst unavailable | $260 | $198.35 | +174.7% | May 8, 2026 |
| RBC Capital | Analyst unavailable | $245 | $185.38 | +158.9% | Apr 24, 2026 |
| Morgan Stanley | Analyst unavailable | $189 | $186.22 | +99.7% | Apr 14, 2026 |
| UBS | Analyst unavailable | $230 | $172.35 | +143.0% | Apr 9, 2026 |
| Truist Financial | Peter Osterland | $210 | $158.91 | +121.9% | Mar 6, 2026 |
| Berenberg Bank | Andres Castanos-Mollor | $153 | $168.42 | +61.7% | Feb 23, 2026 |
| Evercore ISI | Analyst unavailable | $180 | $173.46 | +90.2% | Feb 18, 2026 |
| RBC Capital | Analyst unavailable | $216 | $170.25 | +128.2% | Feb 17, 2026 |
| Wells Fargo | Analyst unavailable | $165 | $166.35 | +74.3% | Feb 16, 2026 |
| Morgan Stanley | Vincent Andrews | $170 | $165.85 | +79.6% | Feb 13, 2026 |
| Mizuho Securities | Analyst unavailable | $185 | $175.43 | +95.5% | Feb 12, 2026 |
| Wells Fargo | Analyst unavailable | $174 | $189.51 | +83.9% | Jan 26, 2026 |
| RBC Capital | Arun Viswanathan | $200 | $178.41 | +111.3% | Jan 21, 2026 |
| Oppenheimer | Analyst unavailable | $207 | $176.56 | +118.7% | Jan 21, 2026 |
| Truist Financial | Peter Osterland | $205 | $172.54 | +116.6% | Jan 21, 2026 |
| HSBC | Analyst unavailable | $200 | $163.04 | +111.3% | Jan 19, 2026 |
| Deutsche Bank | David Begleiter | $185 | $169.33 | +95.5% | Jan 12, 2026 |
| Mizuho Securities | Analyst unavailable | $156 | $167.82 | +64.8% | Jan 12, 2026 |
| UBS | Joshua Spector | $205 | $167.58 | +116.6% | Jan 12, 2026 |
| Scotiabank | Analyst unavailable | $200 | $161.29 | +111.3% | Jan 12, 2026 |
| Robert W. Baird | Analyst unavailable | $210 | $158.15 | +121.9% | Jan 7, 2026 |
| Jefferies | Laurence Alexander | $167 | $143.93 | +76.5% | Jan 5, 2026 |
| RBC Capital | Analyst unavailable | $159 | $134.71 | +68.0% | Dec 18, 2025 |
| Mizuho Securities | Analyst unavailable | $132 | $134.71 | +39.5% | Dec 18, 2025 |
| Truist Financial | Peter Osterland | $125 | $137.01 | +32.1% | Dec 17, 2025 |
| Morgan Stanley | Vincent Andrews | $147 | $133.72 | +55.3% | Dec 16, 2025 |
| UBS | Analyst unavailable | $185 | $119.14 | +95.5% | Dec 5, 2025 |
| Deutsche Bank | David Begleiter | $125 | $128.14 | +32.1% | Dec 3, 2025 |
| Robert W. Baird | Analyst unavailable | $113 | $128.33 | +19.4% | Dec 2, 2025 |
| BMO Capital | Joel Jackson | $136 | $121.39 | +43.7% | Nov 19, 2025 |
| Scotiabank | Analyst unavailable | $85 | $103.65 | -10.2% | Nov 10, 2025 |
| Truist Financial | Analyst unavailable | $87 | $92.74 | -8.1% | Oct 20, 2025 |
| Wells Fargo | Analyst unavailable | $90 | $96.24 | -4.9% | Oct 15, 2025 |
| UBS | Analyst unavailable | $85 | $92.69 | -10.2% | Oct 6, 2025 |
| Mizuho Securities | Analyst unavailable | $92 | $87.61 | -2.8% | Oct 3, 2025 |
| Robert W. Baird | Ben Kallo | $68 | $87.08 | -28.1% | Aug 29, 2025 |
| UBS | Joshua Spector | $89 | $82.71 | -6.0% | Aug 26, 2025 |
| Deutsche Bank | Analyst unavailable | $74 | $68.56 | -21.8% | Aug 4, 2025 |
| Robert W. Baird | Ben Kallo | $60 | $71.58 | -36.6% | Jul 29, 2025 |
| Mizuho Securities | John Roberts | $76 | $71.82 | -19.7% | Jul 15, 2025 |
| UBS | Joshua Spector | $57 | $74.27 | -39.8% | Jul 11, 2025 |
| Piper Sandler | Charles Neivert | $68 | $61.08 | -28.1% | May 14, 2025 |
| Mizuho Securities | Analyst unavailable | $85 | $75.51 | -10.2% | Mar 7, 2025 |
| Morgan Stanley | Vincent Andrews | $68 | $81.21 | -28.1% | Feb 18, 2025 |
| Berenberg Bank | Andres Castanos-Mollor | $102 | $81.65 | +7.8% | Nov 13, 2024 |
| KeyBanc | Aleksey Yefremov | $127 | $98.56 | +34.2% | Nov 12, 2024 |
| Jefferies | Laurence Alexander | $120 | $96.05 | +26.8% | Sep 27, 2024 |
| BMO Capital | Joel Jackson | $150 | $77.81 | +58.5% | Aug 16, 2024 |
| Piper Sandler | Charles Neivert | $90 | $80.4 | -4.9% | Aug 8, 2024 |
| RBC Capital | Arun Viswanathan | $111 | $81.05 | +17.3% | Aug 6, 2024 |
| KeyBanc | Aleksey Yefremov | $132 | $83.8 | +39.5% | Aug 5, 2024 |
| Berenberg Bank | Andres Castanos-Mollor | $83 | $92.51 | -12.3% | Jul 31, 2024 |
| Piper Sandler | Charles Neivert | $95 | $92.77 | +0.4% | Jun 25, 2024 |
| UBS | Joshua Spector | $124 | $112.65 | +31.0% | Jun 13, 2024 |
| Argus Research | Bill Selesky | $166 | $112.65 | +75.4% | Jun 12, 2024 |
| Piper Sandler | Charles Neivert | $122 | $124.38 | +28.9% | May 30, 2024 |
| Scotiabank | Ben Isaacson | $135 | $127.5 | +42.6% | May 21, 2024 |
| Deutsche Bank | Corinne Blanchard | $140 | $130.78 | +47.9% | May 7, 2024 |
| Scotiabank | Ben Isaacson | $150 | $129.65 | +58.5% | May 6, 2024 |
| RBC Capital | Arun Viswanathan | $157 | $128.1 | +65.9% | May 6, 2024 |
| Berenberg Bank | Andres Castanos-Mollor | $160 | $127.65 | +69.1% | Apr 11, 2024 |
| Loop Capital Markets | Chris Kapsch | $162 | $131.17 | +71.2% | Mar 28, 2024 |
| Oppenheimer | Colin Rusch | $308 | $122.66 | +225.4% | Nov 7, 2023 |
| Piper Sandler | Charles Neivert | $155 | $135.32 | +63.8% | Oct 25, 2023 |
| Robert W. Baird | Ben Kallo | $288 | $203.98 | +204.3% | May 15, 2023 |
| KeyBanc | Aleksey Yefremov | $270 | $194.51 | +185.3% | May 11, 2023 |
| UBS | Analyst unavailable | $250 | $235.62 | +164.2% | Jan 11, 2023 |
| Citigroup | Analyst unavailable | $295 | $247.86 | +211.7% | Dec 15, 2022 |
| Morgan Stanley | Analyst unavailable | $155 | $264.64 | +63.8% | Nov 28, 2022 |
| Jefferies | Jonathan Petersen | $320 | $212.04 | +238.1% | Jun 20, 2022 |
| Morgan Stanley | Analyst unavailable | $135 | $242.41 | +42.6% | May 9, 2022 |
| Citigroup | PJ Juvekar | $244 | $190.37 | +157.8% | Feb 18, 2022 |
| UBS | John Roberts | $320 | $190.76 | +238.1% | Feb 18, 2022 |
| Wells Fargo | Edward Kelly | $215 | $190.37 | +127.2% | Feb 18, 2022 |
| Oppenheimer | Colin Rusch | $307 | $196.61 | +224.4% | Feb 17, 2022 |
| Mizuho Securities | Chris Parkinson | $243 | $196.61 | +156.8% | Feb 17, 2022 |
| HSBC | Santhosh Seshadri | $280 | $205.2 | +195.9% | Jan 26, 2022 |
| Cowen & Co. | David Deckelbaum | $275 | $232.62 | +190.6% | Dec 26, 2021 |
| Goldman Sachs | Robert Koort | $205 | $238.9 | +116.6% | Dec 15, 2021 |
| Loop Capital Markets | Chris Kapsch | $280 | $214.42 | +195.9% | Oct 4, 2021 |
| Jefferies | Laurence Alexander | $300 | $218.16 | +217.0% | Sep 30, 2021 |
| Argus Research | Bill Selesky | $278 | $237.75 | +193.7% | Aug 10, 2021 |
| Morgan Stanley | Vincent Andrews | $80 | $158.27 | -15.5% | May 10, 2021 |
Track every rating change on ALB the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlbemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts. The Lithium division supplies a variety of lithium compounds, including lithium carbonate, hydroxide, and chloride, alongside critical reagents like butyllithium. These materials are vital for manufacturing lithium-ion batteries found in electric vehicles and consumer electronics, as well as for high-performance greases, thermoplastic elastomers used in tires and plastics, and as catalysts for chemical reactions, organic synthesis in areas like steroid chemistry, vitamins, and the pharmaceutical industry.…
Historical context
All ALB earningsBasic Materials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AA Alcoa Corporation | FY2026 Q3 · Calendar Q4 2026 | +20.5% | +7.2% | Alcoa: Strong Q3 execution, with safety and transaction risks ahead |
Latest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the ALB recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-19T23:40:43.406631+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-19T23:40:43.403580+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-19. For educational purposes only; not investment advice.